Precision Nanomedicine: A Necessary Convergence of Nanodrug Development, Organotypic Models and Microphysiological Systems
ACS Nano Medicine · 11.02.2026 · 1 (1) · 54-73
DOI: 10.1021/acsnanomed.5c00019 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 08.10.2025. Verfasst von Giulia Silvani und 2 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 205 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Nanoparticle-based therapeutics have been poised to revolutionize medicine for decades. However, despite numerous success stories, translation to the clinic remains hindered by persistent challenges, including toxicity, limited bioavailability, and poor targeting accuracy, which contribute to high failure rates during clinical trials. These limitations stem from the complexity of biological barriers, off-target effects, and patient-to-patient variability in response. Addressing these issues requires more predictive preclinical models that can accurately capture human physiology and disease heterogeneity. In this review we highlight the convergence of nanodrug development with the advent of advanced preclinical testing pipelines, including 3D cell culture with spheroids, organoids and frontier microphysiological systems. We review nanomedicine design criteria with a focus on high efficacy and low toxicity and outline the main barriers to effective disease targeting. Next, we highlight the evolution of 2D cell culture to 3D systems, where advances in nano- and microfabrication have facilitated a rich new ecosystem of biomimetic microphysiological platforms that are accelerating the pace of drug discovery and development. Considering the current stance of regulatory agencies regarding the replacement of animals with human-relevant tissue systems, nanomedicine is at an exciting crossroads with enormous scope to increase the rate of translating nanosolutions from the bench to the bedside.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Silvani, G., Stenzel, M. H., & Kilian, K. A. (2026). Precision Nanomedicine: A Necessary Convergence of Nanodrug Development, Organotypic Models and Microphysiological Systems. ACS Nano Medicine, 1(1), 54-73. https://doi.org/10.1021/acsnanomed.5c00019
Vancouver
Silvani G, Stenzel MH, Kilian KA. Precision Nanomedicine: A Necessary Convergence of Nanodrug Development, Organotypic Models and Microphysiological Systems. ACS Nano Medicine. 2026;1(1):54-73. doi:10.1021/acsnanomed.5c00019
BibTeX
@article{Silvani2026,
author = {Silvani, Giulia and Stenzel, Martina H. and Kilian, Kristopher A.},
title = {Precision Nanomedicine: A Necessary Convergence of Nanodrug Development, Organotypic Models and Microphysiological Systems},
journal = {ACS Nano Medicine},
year = {2026},
volume = {1},
number = {1},
pages = {54--73},
doi = {10.1021/acsnanomed.5c00019}
}
EUVIMED